Autonomic Nervous System Drugs Practice Questions

Q: Alpha-1a adrenergic blocker giving symptomatic relief in benign prostatic hyperplasia (BPH) is:

Tamsulosin. ***Tamsulosin*** - **Tamsulosin** is a **uroselective alpha-1a adrenergic blocker** primarily targeting alpha-1a receptors in the prostate and bladder neck, causing relaxation of smooth muscle and improving urine flow with minimal impact on blood pressure. - This selectivity makes it highly effective for **symptomatic relief of BPH** with a lower risk of orthostatic hypotension compared to non-selective alpha-blockers. *Doxazosin* - **Doxazosin** is a **non-selective alpha-1 adrenergic blocker** that acts on alpha-1 receptors in both the prostate and peripheral vasculature. - While effective for BPH, its non-selectivity leads to a higher incidence of **orthostatic hypotension** and dizziness compared to tamsulosin, as it also lowers blood pressure significantly. *Tolazoline* - **Tolazoline** is a **non-selective alpha-adrenergic antagonist**, primarily used as a vasodilator to treat pulmonary hypertension and peripheral vascular disease. - It is not indicated for the treatment of BPH and has a different pharmacological profile and significant side effects unrelated to prostatic smooth muscle relaxation. *Prazosin* - **Prazosin** is a **non-selective alpha-1 adrenergic blocker** used to treat hypertension and, off-label, for BPH, but it has a short half-life requiring multiple daily doses. - Similar to doxazosin, its non-selective action on vascular smooth muscle can cause significant **first-dose syncope** and orthostatic hypotension, making it less favorable for BPH treatment compared to uroselective agents.

Q: The mechanism of action of botulinum toxin primarily involves disruption of:

Neuromuscular transmission. ***Neuromuscular transmission*** - **Botulinum toxin** acts at the **neuromuscular junction**, specifically targeting proteins involved in **neurotransmitter** (acetylcholine) release. - It cleaves **SNARE proteins** (SNAP-25, synaptobrevin, syntaxin), thereby preventing the fusion of synaptic vesicles with the presynaptic membrane and the subsequent release of **acetylcholine**, leading to muscle paralysis. - This is the primary and most specific mechanism of action of botulinum toxin produced by *Clostridium botulinum*. *Muscle transmission* - This option is too general; while muscle function is affected, the primary disruption is at the **junction between nerves and muscles**, not directly within the muscle fiber itself. - The toxin's action is on the **presynaptic nerve terminal**, preventing the signal from reaching the muscle, rather than interfering with the muscle's internal contraction mechanism. *Non-neuromuscular transmission* - This is incorrect as **botulinum toxin** specifically targets and disrupts the process of **neuromuscular transmission**, not non-neuromuscular pathways. - Its effects are localized to the **cholinergic nerve terminals**, which are abundant at neuromuscular junctions. *Neural transmission* - While it affects parts of the nervous system, stating "neural transmission" is too broad. The toxin is highly specific to the **peripheral cholinergic nerve terminals** at the neuromuscular junction, not general neural transmission throughout the central or peripheral nervous system. - It does not disrupt the conduction of action potentials along the nerve axon but rather the **release of neurotransmitters** at the synapse.

Q: Acetylcholine acting on nicotinic receptors produces:

Contraction of skeletal muscle. ***Contraction of skeletal muscle*** - Acetylcholine (ACh) binds to **nicotinic acetylcholine receptors (nAChRs)** at the **neuromuscular junction**, leading to muscle fiber depolarization and contraction [2]. - These receptors are **ligand-gated ion channels** that allow sodium influx, crucial for initiating muscle action potentials [2]. *Secretion of saliva* - Saliva secretion is primarily mediated by **muscarinic acetylcholine receptors (mAChRs)**, not nicotinic receptors, on glandular cells. - Parasympathetic stimulation, leading to ACh release, increases both the volume and enzyme content of saliva. *Bradycardia* - Bradycardia (slowing of heart rate) is mediated by **muscarinic acetylcholine receptors (M2 receptors)** in the heart [1]. - ACh decreases heart rate by increasing potassium efflux and decreasing cAMP levels in cardiac pacemaker cells [1]. *Pupillary constriction* - Pupillary constriction (miosis) is predominantly controlled by **muscarinic acetylcholine receptors (M3 receptors)** on the pupillary constrictor muscle. - Activation of these receptors causes the circular muscle fibers to contract, reducing pupil size.

Q: Sympathomimetic causing an increase in mean blood pressure, heart rate, and cardiac output on intravenous infusion is:

Adrenaline. ***Adrenaline*** - Adrenaline (epinephrine) acts on **α1, β1, and β2 receptors**. Stimulation of these receptors leads to **vasoconstriction (α1), increased heart rate and contractility (β1), and vasodilation in skeletal muscle (β2)**, resulting in an overall increase in mean blood pressure, heart rate, and cardiac output. - The combined effects on both heart and vasculature contribute to the observed **increase across all three hemodynamic parameters**: mean blood pressure, heart rate, and cardiac output. *Isoprenaline* - Isoprenaline primarily acts on **β1 and β2 receptors**, causing a significant increase in heart rate and contractility, but also leads to widespread **vasodilation** through β2 agonism. - While it increases heart rate and cardiac output, its potent vasodilatory effect often results in a **decrease or no significant change in mean blood pressure**. *Norepinephrine* - Norepinephrine (noradrenaline) mainly acts on **α1 and β1 receptors**, causing strong vasoconstriction and increased heart rate and contractility. - This typically results in a significant **increase in mean blood pressure** and cardiac output, but the reflex bradycardia due to unopposed α1 stimulation often leads to a **less pronounced increase or even a slight decrease in heart rate**. *Phenylephrine* - Phenylephrine is a selective **α1-receptor agonist**, causing potent **vasoconstriction** leading to a significant increase in mean blood pressure. - However, the marked increase in systemic vascular resistance often triggers a **reflex bradycardia**, causing a decrease in heart rate and potentially little change or even a decrease in cardiac output.

Q: Which of the following drugs is least likely to cause sicca syndrome?

Nicotine. ***Nicotine*** - **Nicotine** is a **nicotinic cholinergic receptor agonist** that acts primarily at autonomic ganglia and the neuromuscular junction. - Unlike antimuscarinic drugs, nicotine **does NOT block parasympathetic glandular secretion** and is **not associated with causing sicca syndrome**. - While nicotine has complex autonomic effects, it does **not significantly reduce salivary or lacrimal gland secretion**, making it the **least likely** among these options to cause sicca syndrome. - The question asks for the drug *least likely* to cause sicca syndrome, and nicotine's mechanism of action does not involve blocking secretory glands. *Atropine* - **Atropine** is a potent **muscarinic acetylcholine receptor antagonist** with strong anticholinergic effects. - It directly **blocks parasympathetic stimulation** of salivary and lacrimal glands, leading to marked reduction in secretions. - **Dry mouth (xerostomia) and dry eyes (xerophthalmia)** are classic and prominent side effects, making atropine one of the **most likely drugs to cause sicca syndrome**. *Olanzapine* - **Olanzapine** is an atypical antipsychotic with **moderate anticholinergic properties** due to muscarinic M1 receptor blockade. - **Dry mouth is a common side effect** occurring in 20-30% of patients taking olanzapine. - While less potent than atropine, olanzapine's anticholinergic effects make it **likely to contribute to sicca symptoms**. *Clonidine* - **Clonidine** is an **alpha-2 adrenergic agonist** that reduces sympathetic outflow centrally. - **Dry mouth (xerostomia)** is one of the **most common side effects** of clonidine, occurring in up to 40% of patients. - The mechanism involves decreased salivary gland secretion, making clonidine **highly likely to cause sicca syndrome symptoms**.

Q: Which drug is contraindicated in angle-closure glaucoma?

Atropine. ***Atropine*** - **Atropine** is an **anticholinergic** agent that causes **mydriasis** (pupil dilation) by blocking muscarinic receptors in the iris sphincter muscle. - In angle-closure glaucoma, pupillary dilation can narrow the **anterior chamber angle**, preventing aqueous humor outflow and acutely increasing **intraocular pressure**. *Pilocarpine* - **Pilocarpine** is a **muscarinic agonist** that causes **miosis** (pupil constriction) and contraction of the ciliary muscle, widening the anterior chamber angle. - This action facilitates **aqueous humor outflow**, making it a treatment for, not contraindicated in, angle-closure glaucoma. *Timolol* - **Timolol** is a **beta-blocker** that reduces aqueous humor production, thereby lowering intraocular pressure. - It does not significantly affect pupil size or the anterior chamber angle, making it a safe and effective treatment for various forms of glaucoma, including open-angle. *Dorzolamide* - **Dorzolamide** is a **carbonic anhydrase inhibitor** that reduces aqueous humor production. - Like timolol, it primarily acts to lower intraocular pressure without affecting pupil size or the anterior chamber angle, making it suitable for glaucoma treatment.

Q: Suxamethonium acts on which type of receptors?

Nicotinic acetylcholine receptors. ***Nicotinic acetylcholine receptors*** - **Suxamethonium** is a depolarizing neuromuscular blocker that primarily acts as an **agonist** at the **nicotinic acetylcholine receptors** at the neuromuscular junction [1], [2]. - This initial activation leads to depolarization, followed by a persistent depolarization that prevents further muscle contraction, resulting in **flaccid paralysis** [1]. *Muscarinic acetylcholine receptors* - **Muscarinic receptors** are primarily found in the **autonomic nervous system** and target organs (e.g., heart, smooth muscle, glands), mediating parasympathetic effects [3]. - While acetylcholine does act on these receptors, **suxamethonium** has only weak and clinically insignificant effects here compared to its primary action at the neuromuscular junction. *Adrenergic receptors* - **Adrenergic receptors** (alpha and beta) are activated by **catecholamines** like adrenaline and noradrenaline, mediating effects of the sympathetic nervous system. - **Suxamethonium** does not bind to or exert its primary pharmacological action through these receptors. *Dopaminergic receptors* - **Dopaminergic receptors** are primarily involved in the central nervous system, mediating effects related to motor control, reward, and cognition. - **Suxamethonium** does not target these receptors; its action is peripheral at the **neuromuscular junction** [4].

Q: Which one of the following drugs is not a long-acting neuromuscular blocking agent?

Mivacurium. ***Mivacurium*** - Mivacurium is an **intermediate-duration neuromuscular blocking agent**, typically lasting 15-20 minutes. - Its short duration of action is due to its rapid hydrolysis by **plasma cholinesterase**. *Doxacurium* - Doxacurium is classified as a **long-acting neuromuscular blocking agent**, with effects lasting 90-120 minutes. - It works by competitively blocking the action of **acetylcholine** at the neuromuscular junction. *Pancuronium* - Pancuronium is a **long-acting neuromuscular blocking agent**, with a duration of action of 90-120 minutes. - It is known for its vagolytic effect, which can lead to **tachycardia**. *Pipecuronium* - Pipecuronium is a **long-acting neuromuscular blocking agent**, similar to pancuronium, with a duration of action around 90-120 minutes. - It is an aminosteroid derivative used to produce **skeletal muscle relaxation** during surgery or mechanical ventilation.

Q: Cardioselective β-blocker used in glaucoma?

Betaxolol. ***Betaxolol*** - **Betaxolol** is a **cardioselective β1-adrenergic receptor blocker** that reduces aqueous humor production, making it suitable for glaucoma patients, especially those with pulmonary disease. - Its **selectivity for β1 receptors** minimizes systemic side effects on the lungs (bronchoconstriction) compared to non-selective β-blockers. *Timolol* - **Timolol** is a **non-selective β-blocker** commonly used in glaucoma to reduce intraocular pressure. - It blocks both **β1 and β2 receptors**, which can lead to systemic side effects like bronchoconstriction and bradycardia, making it less suitable for patients with **asthma or COPD**. *Acebutalol* - **Acebutalol** is a **cardioselective β1-blocker** with **intrinsic sympathomimetic activity (ISA)**, primarily used for hypertension and arrhythmias. - While cardioselective, it is **not commonly formulated or indicated for topical ocular use** in glaucoma. *Carvedilol* - **Carvedilol** is a **non-selective β-blocker** with **alpha-1 adrenergic blocking activity**, primarily used for heart failure and hypertension. - It is **not used for glaucoma** as it is not formulated for topical ophthalmic application and its systemic effects are not ideal for this purpose.

Q: The activation of muscarinic receptors in bronchiolar smooth muscle is associated with:

Increase in IP3 and DAG. ***Increase in IP3 and DAG*** - **Muscarinic receptors** on bronchial smooth muscle (M3 receptors) are **Gq protein-coupled receptors** [1]. - Activation of **Gq proteins** leads to the activation of **phospholipase C**, which hydrolyzes **PIP2** into **IP3** and **DAG** [1, 3]. *Inhibition of protein kinase C* - **DAG** (diacylglycerol), produced from the breakdown of PIP2, **activates protein kinase C (PKC)**, rather than inhibiting it [2]. - This activation of PKC contributes to downstream cellular responses, including smooth muscle contraction [1]. *Activation of adenylyl cyclase* - **Adenylyl cyclase** is typically activated by **Gs protein-coupled receptors**, leading to an increase in **cAMP**. - **Muscarinic (M3) receptors** are **Gq-coupled**, so they do not activate adenylyl cyclase; instead, they operate through the phospholipase C pathway [1, 3]. *Opening of Na+/K+ cation channels* - While some neurotransmitter receptors are **ligand-gated ion channels** (e.g., nicotinic receptors), muscarinic receptors are **G protein-coupled receptors** [1]. - Their activation does not directly lead to the opening of **Na+/K+ cation channels**; rather, they initiate intracellular signaling cascades.

Question 1

Alpha-1a adrenergic blocker giving symptomatic relief in benign prostatic hyperplasia (BPH) is:

Accepted Answer

Tamsulosin

Answer

Tolazoline

Answer

Doxazosin

Answer

Prazosin

Question 2

The mechanism of action of botulinum toxin primarily involves disruption of:

Accepted Answer

Neuromuscular transmission

Answer

Muscle transmission

Answer

Non-neuromuscular transmission

Answer

Neural transmission

Question 3

Acetylcholine acting on nicotinic receptors produces:

Accepted Answer

Contraction of skeletal muscle

Answer

Secretion of saliva

Answer

Bradycardia

Answer

Pupillary constriction

Question 4

Sympathomimetic causing an increase in mean blood pressure, heart rate, and cardiac output on intravenous infusion is:

Accepted Answer

Adrenaline

Answer

Isoprenaline

Answer

Norepinephrine

Answer

Phenylephrine

Question 5

Which of the following drugs is least likely to cause sicca syndrome?

Accepted Answer

Nicotine

Answer

Atropine

Answer

Olanzapine

Answer

Clonidine

Question 6

Which drug is contraindicated in angle-closure glaucoma?

Accepted Answer

Atropine

Answer

Pilocarpine

Answer

Timolol

Answer

Dorzolamide

Question 7

Suxamethonium acts on which type of receptors?

Accepted Answer

Nicotinic acetylcholine receptors

Answer

Muscarinic acetylcholine receptors

Answer

Adrenergic receptors

Answer

Dopaminergic receptors

Question 8

Which one of the following drugs is not a long-acting neuromuscular blocking agent?

Accepted Answer

Mivacurium

Answer

Pancuronium

Answer

Doxacurium

Answer

Pipecuronium

Question 9

Cardioselective β-blocker used in glaucoma?

Accepted Answer

Betaxolol

Answer

Timolol

Answer

Acebutalol

Answer

Carvedilol

Question 10

The activation of muscarinic receptors in bronchiolar smooth muscle is associated with:

Accepted Answer

Increase in IP3 and DAG

Answer

Inhibition of protein kinase C

Answer

Activation of adenylyl cyclase

Answer

Opening of Na+/K+ cation channels

Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?